Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Intellipharmaceutics International Inc (IPCI.TO)

Intellipharmaceutics International Inc (IPCI.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Intellipharmaceutics International Inc 30 Worcester Road Toronto ON M9W 5X2 CAN

P: 416-798-3001

Sector:

Medical

INDUSTRY GROUPING:

TSX Biotechnology

Description:

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.

Key Statistics

Overview:

Market Capitalization, $K 2,647
Shares Outstanding, K 33,093
% of Institutional Shareholders 0.63%

Financials:

Annual Sales, $ 66 K
Annual Net Income, $ -2,892 K
Last Quarter Sales, $ 69 K
Last Quarter Net Income, $ -1,889 K

Growth:

1-Year Return 0.00%
3-Year Return -54.29%
5-Year Return -85.96%
5-Year Revenue Growth -58.75%

Per-Share Information:

Next Earnings Date 10/13/23
Earnings Per Share ttm -0.09
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year -29.23%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 09/14/18

IPCI.TO Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % N/A
Return-on-Assets % -211.39%
Profit Margin % -4,400.55%
Debt/Equity N/A
Price/Sales 2.38
Price/Book N/A
Book Value/Share -0.53
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar